The report of a new class of potent and highly selective inhibitors of Bcr-abl highlights the potential for a truly leukemia-specific drug with no expected off-target activity. GNF-2, as a representative compound of this class, may have inspired the identification of a region of Bcr-abl that is amenable to drug design, just as imatinib did almost a decade ago.
This is a preview of subscription content, log in via an institution to check access.
References
Druker, B.J. et al. Nat. Med. 2, 561–566 (1996).
Adrian, F.J. et al. Nat. Chem. Biol. 2, 95–102 (2006).
Schindler, T. et al. Science 289, 1938–1942 (2000).
Goldman, J.M. & Melo, J.V. N. Engl. J. Med. 349, 1451–1464 (2003).
Branford, S. et al. Blood 102, 276–283 (2003).
Azam, M., Latek, R.R. & Daley, G.Q. Cell 112, 831–843 (2003).
Carter, T.A. et al. Proc. Natl. Acad. Sci. USA 102, 11011–11016 (2005).
Nagar, B. et al. Cell 112, 859–871 (2003).
Posner, B.A. Curr. Opin. Drug Discov. 8, 487–494 (2005).
Acknowledgements
The authors would like to thank Dick Leopold for his thoughtful review of the manuscript and Chris Faehnjle for his assistance in the preparation of the figure.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohren, J., Sebolt-Leopold, J. Inhibitors of Bcr-abl... breaking new ground again. Nat Chem Biol 2, 63–64 (2006). https://doi.org/10.1038/nchembio0206-63
Issue Date:
DOI: https://doi.org/10.1038/nchembio0206-63
- Springer Nature America, Inc.